Unsubstantiated Benefits: University of Gothenburg Cautions Against Widespread CGM Adoption in Healthy Adults

August 9, 2026

University of Gothenburg Sweden

Overview

A recent review from the University of Gothenburg highlights a critical lack of scientific evidence supporting health improvement or disease prevention benefits from continuous glucose monitoring (CGM) in healthy individuals. The researchers warn that the extensive data generated by CGMs for this population carries risks of unnecessary dietary restrictions, anxiety, and potential misallocation of healthcare resources. While acknowledging CGMs’ established value for diabetes management, the study advocates for a highly cautious approach to their broader use in non-diabetic populations.

In Depth

Key Findings: Lack of Evidence for Healthy Populations

An extensive review conducted by a research group at the University of Gothenburg, Sweden, concludes that there is insufficient scientific evidence to substantiate claims of health improvement or disease prevention through the use of continuous glucose monitoring (CGM) in healthy individuals. The review cautions that the real-time blood glucose data provided by CGMs, while invaluable for diabetes management, may not consistently offer benefits to healthy users and can even lead to misinterpretation and unwarranted health anxiety. While CGMs are well-established for their utility in managing diabetes and reducing the need for finger-prick tests in patients, the study calls for a more rigorous evaluation before their widespread adoption by healthy populations.

Technical Nuances and Clinical Implications

CGM devices function by continuously measuring interstitial fluid glucose levels via a small, subcutaneously inserted sensor. This data is transmitted in real-time to smartphone applications, enabling users to observe the immediate impact of factors such as diet, exercise, and sleep on their glucose profiles. A critical distinction highlighted by the review is that blood glucose levels in healthy individuals naturally fluctuate within a physiological range. The risk arises when minor, normal variations reflected in CGM data are misinterpreted as ‘abnormal’ or indicative of pathology. Such misinterpretations can precipitate unnecessary and potentially harmful dietary restrictions, jeopardizing both physical and mental well-being. For example, a naturally occurring post-meal glucose rise, which is typical for healthy individuals, might be mistakenly viewed with alarm, prompting users to avoid nutritionally beneficial foods like fruits and whole grains.

Market Expansion and Ethical Considerations

The continuous glucose monitoring market has seen a significant expansion beyond its traditional base of diabetic patients, increasingly targeting the general consumer, particularly the growing health-conscious demographic. Many companies actively promote CGMs as essential tools for ‘health optimization’ and ‘disease prevention,’ despite a persistent lack of robust scientific evidence to support these broad claims for healthy individuals. This raises significant consumer protection concerns, as individuals may make critical health and lifestyle decisions based on unproven benefits. Furthermore, from a healthcare resource management perspective, the widespread adoption of CGMs by healthy individuals could inadvertently divert resources crucial for actual diabetes diagnosis and treatment, or contribute to an increase in unnecessary medical consultations. Societally, an excessive focus on CGM data among healthy populations risks skewing public health priorities away from evidence-based interventions.

Strategic Outlook and Regulatory Imperatives

Future research must prioritize rigorous, long-term clinical trials to thoroughly investigate the effects of CGM use in healthy individuals, with particular attention to psychological impacts, behavioral modifications, and verifiable health outcomes. Concurrently, efforts are underway to integrate CGM data with other biosignals—such as activity levels, sleep patterns, and genetic information—to develop truly personalized and clinically validated health management solutions. However, before advocating for widespread adoption, it is imperative to establish clear medical benefits for healthy individuals and to implement appropriate guidelines and information dissemination strategies to prevent misuse and misinterpretation. Regulatory bodies will likely need to re-evaluate approval criteria for CGMs marketed to healthy individuals and mandate transparent information disclosure to empower consumers with the knowledge required to make informed and evidence-based health decisions.

Source: https://www.news-medical.net/news/20260804/Continuous-glucose-monitors-show-no-proven-benefits-for-healthy-people.aspx

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.